Upcoming Events
Log In
Pricing
Free Trial

World Beyond PIRADS: Updates in Prostate MRI, Dr. Jyothirmayi Velaga (9-30-26)

HIDE
PrevNext

0:02

Hello, and welcome to Noon Conference hosted by Modality.

0:05

Noon Conference connects the global radiology community through free live

0:09

educational webinars that are accessible for all and is an opportunity to learn

0:13

alongside top radiologists from around the world.

0:15

Today, we are honored to welcome Dr.

0:17

Jyothi Veluga for a lecture entitled World Beyond PI-RADS: Updates in Prostate MRI.

0:23

Dr. Veluga completed her radiology residency in India and Singapore, and currently

0:27

she is an abdominal radiologist at St Vincent's Hospital, Sydney, with a

0:31

subspecialty focus on prostate and colorectal imaging.

0:35

At the end of the lecture, please join her in a Q&A session where she will address

0:38

questions you may have on today's topic.

0:41

Please remember to use that Q&A feature to submit your questions so we can get to

0:44

as many as we can before time is up. With that, ready to begin today's lecture, Dr.

0:49

Veluga, please take it from here.

0:52

Thank you, Ashley, for the kind introduction, and thank you, all of you, for being

0:56

here, giving me this opportunity to share space with you.

1:00

And also special thanks for moving the Noon Conference to evening, so that it's

1:06

morning time for me. So I'm based in Sydney, and this is the hospital

1:12

that I work in, St. Vincent's Hospital.

1:14

I'm currently sitting right here, and

1:19

this is the view from my apartment building, which is quite close to the hospital.

1:23

As you can see, there's a little bit of bay, and we've moved into spring now, so

1:27

really amazing weather. And in the next 30 to 40 minutes, we're going to look at

1:33

a few case examples of updates in prostate imaging.

1:38

I have no disclosures, and the objectives of this talk are essentially to

1:42

familiarize ourselves with different reporting systems that are available besides

1:46

PI-RADS, for example, for active surveillance or post-treatment assessments or even

1:51

image quality. So just as an introduction, we all are well-versed with PI-RADS

1:56

scoring. It's used in diagnosis of prostate cancer, especially to look at the

2:02

likelihood of a clinically significant prostate cancer.

2:06

But once we've identified the cancer and say we've treated it, the rules change,

2:11

and it may be difficult to apply the PI-RADS framework.

2:14

And there are also now scenario-based reporting systems that are available, which

2:19

we're going to look at those examples with a few cases.

2:24

So the first case I've got here is a 65-year-old male patient with positive family

2:29

history. He's on active surveillance.

2:31

So a quick word on what active surveillance actually means.

2:35

So this is an established management strategy for low risk or favorable

2:39

intermediate-risk prostate cancer.

2:41

That is, we're looking at 3+3 or favorable 3+4 lesions, and this usually involves

2:47

close monitoring through PSA, DRE examination, MRI, or plus-minus biopsy.

2:53

So the intent here is still curative, meaning we follow up these patients year on

2:57

year with still an intent to cure if things change.

3:02

So, coming back to the first case. So what you see here is, we see a focal area

3:09

at the right posterior peripheral zone.

3:11

It's T2 dark, and there's also a DWI, can't really assess much.

3:17

Its plus-minus image quality is not that great.

3:19

But in ADC, there's a little bit of low signal intensity.

3:23

So based on this, it would've been PI-RADS 3, but because it is also DC

3:29

positive, it's upgraded to PI-RADS 4. Now, I've got the comparison in the top row.

3:34

So this was from four years prior. And when we compare the prior and the current

3:39

one, so what you see is that there's not much change.

3:42

Essentially, the lesion has remained stable.

3:45

So what we have is PI-RADS lesion, which has been stable for the last four years.

3:49

But we know that PI-RADS is usually for standard detection, but it doesn't really

3:54

address or talk about the longitudinal change that has happened over

4:00

these two different time points. So for that, we use this scoring system.

4:06

It's called PRECISE. It's prostate cancer radiologic estimation of change in

4:11

sequential evaluation. So essentially, it allows us to monitor

4:16

these cases where there's not been any treatment or intervention, and we can

4:19

actually look at different time points and see if there's been any change compared

4:25

to the previous MRIs. So unlike PI-RADS, it allows for the serial assessment of

4:31

change between scans. So, this is PRECISE version one.

4:35

I think it was published about, basically, in 2017.

4:38

This is very similar to PI-RADS in the sense it also gives the one to five Likert

4:44

scale, and you can think of it like a traffic light system.

4:47

Essentially, PRECISE 3 is stable changes.

4:51

Anything below PRECISE 1 and 2 are changes are getting better.

4:56

And if it's PRECISE four and five, it's actually progress of disease.

5:00

And so, does it really predict outcomes?

5:02

So there are few studies at the moment, but I would like to highlight this

5:07

particular study in 2021, where they saw that if the PRECISE

5:13

scoring was one, two, three, meaning either it's stable or gotten better,

5:19

95% of these patients had no clinical progression.

5:23

Whereas if the PRECISE scoring was four to five, meaning there was either increase

5:28

in size of the lesion or a change in radiology stage, 61% of

5:34

these patients actually had clinical progression.

5:38

But then the version one did come with some limitations.

5:40

For example, there is no standardized way of measuring the lesion, so that

5:46

means that there can be high variability between radiologists who are reading the

5:50

scans. And there's also a bit of scoring ambiguity.

5:53

The criteria are not really clearly defined for PRECISE4 or PRECISE5, again,

5:59

which means that there can be quite variability between reading radiologists.

6:05

So the version two came up with changes.

6:08

One of the important change is integration of image quality, which was not in the

6:13

earlier version. Now, we're going to look at it later on, and there's also clear

6:17

definition of what baseline means.

6:19

For example, like the earliest MR.

6:23

And the PRECISE code three, which is stable changes, has been split into whether

6:28

it's visible change or a non-visible change, meaning if the lesion is visible and

6:33

the changes are stable, it's 3V, which is visible stable.

6:37

And say, if it has stable MR appearance, but we don't really see the lesion, it can

6:42

be categorized as 3NV. And also another new scoring system, which is PRECISEX,

6:48

which means that for whatever reason, the study is non-diagnostic and cannot be

6:53

really assessed. So this is the PRECISE version two.

6:58

Again, it's a five-point Likert scale.

7:00

It's just that the PRECISE3 scoring has now been split into visible and

7:05

non-visible, and then we do have this X category, say for example, if the image

7:09

quality is non-diagnostic. And there's also consensus reporting requirements and

7:14

also recommendations. One is dual comparison.

7:17

It's kind of similar to, say for example, MR-rectum, where we look at

7:22

post-treatment changes. We look at the immediate prior as well as the baseline MR.

7:27

Similarly, here for PRECISE, we do look at the immediate prior as well as the

7:32

baseline MR. And also the score assignment is, we do apply

7:38

PRECISE score for each lesion, and the highest score is the scoring of the entire

7:45

study. And we still apply PI-RADS category for each individual

7:51

lesion. And there is a bit more definition in terms of what increased means

7:57

in the version two. For example, if you look at the volume, significant volume

8:01

change has been defined as 50%. And also the minimal time interval between two

8:07

scans also is at least one year. So now, let's apply what we've just

8:13

seen in this particular case. So what you see is PI-RADS four lesion.

8:16

It's been stable since the last four years.

8:19

So essentially, we have a PI-RADS four lesion.

8:21

Because it's stable, we've given a scoring of PRECISE3, and because it's visible,

8:25

it's 3V. So the key points for this case is PRECISE allows for

8:31

longitudinal assessment of progression, unlike PI-RADS, and it's important to

8:36

compare with the recent prior as well as the baseline, and it's best to actually

8:41

talk about lesion in volume, which means that we need to give three dimensions

8:47

to be able to obtain the volumes. Okay. So now let's look at case two.

8:53

So I've got a 68-year-old male patient, previously Gleason 3+3, now on active

8:58

surveillance. This is a current study where he had increased PSA, and the question

9:03

was, is that progression? So what you see here is a small lesion at the right

9:08

posterior peripheral zone with protostatic diffusion Early enhancement, it's dark

9:14

on T2. So essentially what we're seeing is a small volume PIRADS 4 lesion.

9:19

So now that I've got the priors in the top row, so if we look at the prior also

9:24

PIRADS 4 and the current one, we can see that the lesion has increased in size.

9:29

It also looks a lot more conspicuous.

9:31

So essentially, there's progression from previous to current.

9:34

So this is still a PIRADS 4 lesion, but when we apply PI-RADS scoring, it's PI-RADS

9:39

4. So 4 means there is progression in terms of either increase in size

9:45

or increase in conspicuity of the lesion, or if there's a new lesion.

9:50

So what about image quality, because that's also part of the current

9:55

active surveillance assessments for MR.

9:57

So before we move into how to assess image quality, just to refresh our memories of

10:03

what the PIRADS version 2.1 technique actually is.

10:07

Say, these are the current guidelines, and for T2 images, the recommendation is the

10:13

slice thickness needs to be three millimeter without any gaps.

10:16

And the current recommendation says one axial and at least one orthogonal plane,

10:22

that is sagittal or coronal. But at least in my practice, most centers here we do

10:26

three-plane T2s. And for diffusion-weighted imaging, the slice thickness needs

10:32

to be four millimeter or less, and the high b-value needs to be at least 1,400 or

10:38

more, which can be either acquired or calculated.

10:42

And ADC map needs to be generated at least from two b-values, and the highest

10:47

b-value needs to be less than 1,000.

10:50

And for DCE, again, the slice thickness is three millimeter, the temporal

10:53

resolution needs to be 15 seconds or less, and with fat suppression.

10:58

And if there's no fat suppression, at least subtraction needs to be available.

11:02

So now, why does image quality matter?

11:06

So another study that published with PIQAL version one, which is the scoring system

11:12

for assessment. So what they've seen that is if the image quality is less, at least

11:18

a quarter of the cases had pathological upstaging, and there's also almost a

11:23

quarter of the cases were actually non-diagnostic.

11:26

And if you look at the middle number, it's about one-fourth of the cases where

11:30

PIRADS 5 was not assessed, meaning it was really challenging for assessment, for

11:36

example, for APE.

11:39

So how does this help? What does this mean for us actually when we do MR

11:45

readouts? So PIQAL is the current scoring system that's available for

11:51

quality assessment. So it stands for prostate imaging quality and MR

11:56

interpretation, for MR interpretation.

11:58

And say if the PIQAL scores are low, as we've seen in the previous slide, there's a

12:04

high chance of missing or under-detecting csPCAs.

12:08

And if the scoring is high, meaning the image quality is good, it is associated

12:13

with fewer equivocal PIRADS 3 classifications and also better readouts in terms of

12:19

local staging, especially when we're looking at extraprostatic extensions.

12:24

So this is the PIQAL version one. Again, this was a five-point scale,

12:29

but this has been revised recently with three scoring system, and it's quite simple

12:35

to understand, meaning if the scoring is one, essentially the study is inadequate.

12:41

If the scoring is two, it's acceptable, and of course, three is the best-case

12:45

scenario. So this is a scoring sheet available on the

12:51

paper here. So what essentially we do is to score each sequence

12:57

with these available metrics and then submit this into this chart.

13:03

So the main difference between PIQAL version one and version two, besides reduction

13:09

of the scoring system from five to three, version two can also be applied for

13:13

biparametric, not just multiparametric MRI.

13:16

But the cases today we're going to see are multiparametric, so we're just going to

13:20

stick to the bottom flowchart. And let's apply this flowchart to the

13:26

case two. So you have to take my word for it that all the scorings for T2 and DWI

13:31

were four, and then DCE was also optimal.

13:35

So essentially, we have a score of three, which means this is an optimal study.

13:40

But what about the scoring for the previous case, where I said the diffusion was

13:44

quite challenging to read? So the diffusion scoring was about two, but the

13:50

DCE was optimal. And because the T2 was also optimal, this can be

13:56

upgraded to two. So which means that it's still acceptable for us to make a read

14:01

from this study. So the key point here is, say, even if one of the

14:08

sequences is a bit of a challenging image quality, if the rest of the sequences are

14:14

okay, it can still be an acceptable scan.

14:17

So the key points for this case is the image quality assessment system that's

14:22

currently available is PIQAL version two, and this can be applied for both

14:26

biparametric as well as multiparametric MRI.

14:29

And you can kind of use DCE as a safety net.

14:33

But at least one of the sequences, either T2 or DWI, needs to score four out of

14:37

four. And if you think about it, it's quite intuitive, meaning if the image quality

14:42

is good, readouts are also going to be good.

14:46

So let's look at this case three for active surveillance.

14:50

So this is a 74-year-old male patient with 3 plus 4 equals 7

14:56

favorable

14:57

Gleason score, with now question of whether this is progression or not.

15:03

So this patient's on active surveillance, and what we see is this PIRADS 5 lesion.

15:08

We have the previous at the top row and the current at the bottom row.

15:11

So we've got T2 dark lesion, restricted diffusion, as well as positive DCE, so

15:15

PIRADS 5. And there's no APE, so the staging is T2.

15:21

So when we look at these two studies, there's not much difference.

15:24

So essentially what we're seeing here is PI-RADS scoring of 3, which means stable,

15:29

and we can still see the lesion, so this is visible, so it's 3V.

15:33

And when we apply the PIQAL scoring of image quality, everything is like tick box.

15:38

So this is a good study, so it's PIQAL 3 scoring.

15:44

And say, for example, for the same case, if we see extraprostatic extension in the

15:50

new study, that means that there is actually progression of staging from T2 to

15:56

T3. If that happens, this PI-RADS scoring would be PI-RADS 5.

16:00

So the key point for this case is essentially PIRADS and PI-RADS, they give really

16:06

different information. Say, for example,

16:11

the lesions can be PIRADS 5, but the PI-RADS can be 3.

16:15

But in the previous case, we've seen that it's a really tiny PIRADS 4 lesion, but

16:19

the PI-RADS scoring was four. So essentially, the PI-RADS talks about how things

16:24

have changed compared to the previous studies, where PIRADS actually talks about

16:28

the likelihood of a csPCA for a particular lesion at any time point.

16:34

So that's something to remember. And case four, I've got another case, also on

16:39

follow-up, but for watchful waiting.

16:40

So this is a 72-year-old male patient with increased PSA of

16:45

14.9. And the top row, I've got the previous imaging, and I've got the latest at

16:51

the bottom row.

16:53

And what we see here is multifocal disease, and this was a really high-grade lesion

17:00

for this 5 disease. And this is slightly different from active surveillance,

17:05

meaning

17:07

when you talk about watchful waiting, there's not a curative intent, unlike active

17:12

surveillance, where the intent is still to cure the patient if things change.

17:16

So this is mostly done, for example, for elderly patients or if their palliation

17:22

is required or just supportive measures, but not really a clear intent to treat.

17:27

So that's the difference between watchful waiting and active surveillance.

17:35

So now we'll switch gears to the next assessment examples.

17:41

So this is a case of prior radiotherapy, and the patient has come back with PSA

17:45

recurrence. So just a brief introduction of what scoring system's available for

17:51

whole gland therapy. So when we think about whole gland therapy, there are two

17:56

domains. One is whole gland radiotherapy, the other one is prostatectomy.

18:01

So there's slight differences between these two in terms of how we apply the

18:06

scoring system. And again, this is also a five-point Likert scale.

18:10

If then we say three, we're a little bit uncertain if there is recurrence.

18:14

When we say one and two, the likelihood of recurrence, our suspicion is low.

18:18

And when we say four and five, the suspicion is high.

18:23

But most of the times, at least in my practice, because I'm actually sitting in a

18:28

heartland PSMA. So most of these cases would go on to have PSMA, because

18:34

one of the limitations for applying this scoring system is that we're able to

18:39

assess only the prostate gland and not metastasis.

18:42

So

18:43

sometimes the patients may directly go to PSMA, or sometimes they may come for MR.

18:48

So the challenges for, say, radiotherapy assessment is

18:54

multifold. One, is because of radiotherapy, the gland itself shrinks, it becomes

18:59

fibrotic, and the T2 can be quite challenging to assess.

19:03

Sometimes we may even lose distinction between the transition zone and the

19:07

peripheral zone, and it makes it difficult to apply PIRADS framework.

19:12

And also if there are any, say, fusion markers or even--

19:18

Then there's a lot of artifacts and it's quite challenging to read the DWI.

19:23

So in these scenarios, DCE becomes the dominant sequence.

19:28

But for post-radiotherapy, we do have an option to look at DWI and DCE,

19:34

and we can drive the scoring depending on where we see the lesion best, whether

19:40

it's DWI or DCE. We'll just see an example.

19:43

And it's okay if you don't

19:46

remember this or get this, you can just have a look at it in the article, say, if

19:50

you choose to apply this scoring. So for this particular case, the scoring for DWI

19:55

was four, because what we saw was this positive DWI,

20:01

meaning this restricted diffusion, this positive DCE.

20:04

So when we go back and look at on the table, the scoring for DWI was four, and the

20:09

scoring for DCE was four. And I want to highlight that for this particular case, I

20:15

didn't have priors, so I didn't know where the primary site of the lesion was.

20:19

So if we don't know the primary site of the lesion, or if the new abnormality is

20:25

elsewhere, than the prior lesion, the scoring would be four.

20:31

But if it's at the same site of the lesion, the scoring would be five for each

20:35

individual sequence. So let's apply this framework for this particular case.

20:40

So we know that our scoring was four for both DCE and DWI, and

20:46

I do see the lesion quite well in DWI. So let's stick to the left side table.

20:51

So the scoring is four. So, next we look at the DCE.

20:55

So the DCE scoring was also four, and it just so happens that both these

21:00

abnormalities are matching, meaning they're at the same site.

21:03

If that happens, this is upgraded to five.

21:06

So that's how you apply a PIRR scoring to post-radiotherapy changes.

21:11

Again, local recurrence after radiotherapy, it usually occurs at the site of the

21:15

original tumor in more than 90% of the cases.

21:19

Then it kind of makes sense as to why if you see the abnormality of the same site,

21:24

the scoring for individual sequences would be scored five.

21:28

And after treatment with radiotherapy, the dominant sequences would be DCE and DWI.

21:34

And especially when the gland is really shrunken and fibrotic, it's important to

21:39

look for early enhancement and restricted diffusion in these glands.

21:43

T2 can be quite challenging to look at.

21:46

So let's look at the next case, which is a post-prostatectomy case.

21:50

And again, tumor site was not known, quite a remote surgery.

21:55

So what we see here is a large focal mass at the root of the seminal vesicle on

22:01

the right side. It shows early enhancement, quite bright, and also restricted

22:07

diffusion. So we know that this is a recurrence already, but how do we apply PIRR

22:13

in this case? Again, so when we look at the scoring matrix, both the DWI and DCE

22:18

have score four, and let's apply that

22:22

in this flowchart. So as I said, for radiotherapy and prostatectomy, the current

22:28

available assessment criteria is PIRR, but there's slight differences between these

22:33

two. So let's look at this chart. So the dominant sequence here is DCE.

22:38

So we said that it got score four and DWI was also scored four.

22:43

So essentially, the overall scoring is four.

22:45

So this is a recurrent disease at the right seminal vesicle bed with PIRR scoring

22:50

of four. So the important thing for prostatectomy is knowing where the site of

22:56

relapses commonly occur. So there are multiple sites, but these two sites are

23:00

really common. One is vesicourethral anastomosis, the other one is the residual

23:05

seminal vesicles. And for post-prostatectomy, unlike radiotherapy, DCE is

23:11

the dominant sequence.

23:13

So now we're switching gears to focal therapy, again, my most favorite part of the

23:18

talk. So this is case seven, and this is a proven decent grade three plus

23:24

four cancer. And what we see here is a focal lesion in the anterior right side of

23:29

the gland. And this case has come in for focal therapy assessment.

23:33

And there's a reason why I've given you biparametric MR images, shared only these

23:38

images here. So we've got a T2, we've got DWI, and ADC.

23:43

So if we just look at these images, this would be PIRADS-4, because the lesion is

23:48

less than one point four centimeter, and it's mostly anterior involving the

23:53

transition zone.

23:55

So when we look at focal therapy, there are quite a few options that are available.

24:01

So my experience is based on cryotherapy and IRE, so I'm just going to stick to

24:06

those two. So in cryotherapy, as the name implies, there's cycles of freezing and

24:11

thawing that cause cell death. But when we look at IRE, it usually uses electrical

24:17

pulses to cause ablation of the lesion.

24:20

So now let's relook at this case. So now we've got the DCE

24:27

image here. So when we compare the DWI, ADC, and the DCE, on DCE,

24:33

there's a lot more area that's enhancing early, which means that the lesion is much

24:38

larger than we thought it was before. So now it's PIRADS five.

24:42

But what's even more important is that it is periurethral in location.

24:46

It extends to around the urethra. So as I said,

24:51

at least in my previous institution, Singapore, where I've worked, there were two

24:55

options for focal therapy. One was cryotherapy, the other one was IRE.

25:00

So because this case has a lot of cancer extending to the periurethral

25:05

region, focal cryotherapy may not be the best option because in cryotherapy,

25:11

there's a warming catheter in the urethra, and because it's warming, we may not

25:15

freeze the cells

25:19

well enough for cell death around the periurethra.

25:23

So this is an ideal candidate for IRE.

25:26

So this is the importance of having the full set of assessment, and then decide as

25:31

to what treatment options this patient might benefit from.

25:35

So the main point for this case is the importance of DCE.

25:40

Again, if there's one takeaway from this entire talk, it's the importance of DCE,

25:45

especially in post-treatment cases.

25:47

So there are studies that have shown that DCE does reflect tumor extent

25:54

that's correlated well with histology, and especially now there is a lot of

25:58

interest in biparametric MRI, and if the consideration of treatment is focal

26:04

therapy, a DCE would be really helpful to be part of the assessment criteria.

26:11

So now let's look at how do we assess these patients after focal therapy.

26:15

So when we look at focal therapy, there are two different

26:19

areas where we can assess the gland.

26:22

So let's talk about the out-of-field recurrence.

26:25

So when we say out-of-field recurrence, this is the untreated gland we're talking

26:29

about. So we still use PIRADS version 2.1 in these areas.

26:33

But when we look for recurrence at the region of treatment, there are two options.

26:38

One is PiFAB and the other one is TARGET.

26:41

So what do we mean by in-field recurrence?

26:44

Either the recurrence is within the ablation cavity or just at the margins of the

26:49

ablation cavity. So as I said, there are two scoring systems that are available at

26:54

the moment. One is PiFAB. This was actually from a single institution from the

27:00

UK, whereas TARGET is actually multi-group consensus.

27:06

And for our dataset, we've applied both, and both really work well.

27:11

And this is a brief introduction of what PiFAB is.

27:15

So again, for focal therapy, DCE is the dominant sequence as well.

27:21

And for PiFAB, there's an order in which there's a recommendation as to how we

27:27

approach these cases. So we look at DCE first, and then we look at restricted

27:31

diffusion and T2, and each sequence has a specific criteria that needs to be

27:37

looked at. We'll have a look at in the next slide.

27:40

And unlike PIRADS or PIRR PI-FAB actually is a three-point

27:46

scoring system, one being low index of suspicion for recurrence, two meaning

27:51

intermediate findings, three meaning high probability of recurrence.

27:57

So this is the table that talks about as to what we need to look for

28:02

in each sequence. We'll look at this again with the case example.

28:06

So this is one-year follow-up for the same patient that we saw before, which shows

28:11

the expected typical post-ablation changes with cavity with a little bit of fluid

28:16

inside, but it doesn't really show any restricted diffusion, and I do not really

28:22

see any contrast enhancement. So let's apply PI-FAB for this case.

28:27

So as I said, the dominant sequence is DCE, so let's start there.

28:31

So we don't see any early enhancement, which means that it falls under this

28:34

category of no enhancement. So it's essentially a PI-FAB one score.

28:41

And we can look at the T2 and DWI as well.

28:44

There's absolutely no restricted diffusion, and this is the expected post-treatment

28:49

change for focal therapy. So the probability for recurrence is

28:55

quite low in this case, so this is a PI-FAB one. So what about TARGET?

28:59

So how do we look at TARGET? So TARGET is more of a two-tiered system.

29:03

So we first look at DCE, which is the major sequence, and then use DWI and T2 as

29:09

joint minor sequences. So each sequence, for example, whether it's DCE or

29:14

DWI or T2, they get three scores, whether, say for example, if you're looking at

29:19

DCE, are the findings non-suspicious? Are the findings equivocal?

29:24

Are the findings suspicious? And based on that, everything is summated to get a

29:28

five-point score. So again, it's a five-point score similar to other

29:35

scoring systems that we've seen. One and two, this index of suspicion is quite low,

29:41

three is intermediate, and four and five, index of suspicion is quite high.

29:46

So this is what I meant by giving a score for each and every sequence.

29:51

So let's take an example for DCE. So if we see no early enhancement or there is

29:56

some focal late enhancement, the scoring is one for DCE, which means that it's a

30:02

non-suspicious finding. But if the enhancement pattern is focal and nodular or

30:07

maybe thin and linear, it's a little bit equivocal, so that falls under two.

30:12

And if there's early enhancement, quite strong nodular enhancement, it's actually

30:16

suspicious features, that would be three.

30:21

So let's look at this case and see whether we can apply TARGET here.

30:27

So let's look at DCE first. So when we look at DCE, there's absolutely no early

30:30

enhancement, which means that the DCE score is non-suspicious, and which falls in

30:35

one. So the easiest way to approach TARGET is, say, for example, if the DCE is one,

30:41

that is there's nothing suspicious in DCE, the overall scoring can't be more than

30:45

one or two if you look at this table.

30:48

So it doesn't really matter,

30:51

the nitty-gritty of DWI and T2 doesn't matter because it wouldn't really go beyond

30:56

one or two, which is still low index of suspicion.

30:59

And if the DCE is three, and the cumulative score is already high suspicion, so

31:05

the gray area is essentially two, and then we need to look at how do we then

31:10

apply DWI and T2 to assess the overall score.

31:16

So for the key point for this case is for post-focal therapy, DCE is the dominant

31:21

sequence, irrespective of whether you're applying PI-FAB or TARGET.

31:27

So this is another case. Again, this is one-year post-cryotherapy.

31:31

The index lesion was Gleason three plus four, and this patient was treated with

31:35

focal cryotherapy. So what we see here is expected post-ablation change of the

31:40

right posterior epididymal zone.

31:43

And I don't see any DWI abnormality, nothing bright on DWI, but I do see a

31:49

tiny little bit of dot or dark focus in ADC, and this may be

31:55

really subtle, mild nodular enhancement on DCE.

31:58

So now there are some findings in this. So let's apply PI-FAB for this case.

32:03

So let's start with DCE. So we do see this subtle enhancement, which is

32:09

less than three millimeters. So the PI-FAB scoring would fall

32:13

in this mid-section. And when we look at T2, it's quite low, and then

32:19

DWI is also low. So this would be intermediate category for PI-FAB.

32:24

And what about TARGET? So let's start again with DCE, right?

32:28

So there's a small focus of enhancement, which is about

32:32

intermediate equivocal finding, which would be DCE two.

32:36

Now let's look at T2 and DWI. So the DWI is still low, so

32:42

which is non-suspicious, which is one.

32:44

And when we look at T2, it's also quite dark. Again, it's a score of one.

32:49

So essentially, we're looking at one, maybe two for DWI and T2.

32:54

So this would become TARGET three, so which means that it's still equivocal.

33:00

So the risk of or likelihood of recurrence in this case is equivocal.

33:04

So this patient was biopsied, and the biopsy turned out to be negative, and we do

33:08

have a few more years of follow-up for this patient with negative biopsy.

33:12

So the key point here is that fibrosis, especially in the setting of focal

33:17

therapies, can be quite low on ADC.

33:19

So it's always important to read ADC along with DWI.

33:23

So if we go back to this case, we do have some dark spot on DWI, but there's

33:27

nothing suspicious on-- I'm sorry, dark spot on ADC, but nothing suspicious on

33:33

DWI. So it's important to read them in conjunction and not just rely only on ADC in

33:38

this patient population.

33:41

And now moving to the last case. So I've got pre-treatment images on the top row,

33:47

and I've got the post-treatment images follow-up in the bottom row.

33:51

So pre-treatment, we see a focal lesion in the anterior right hemigland,

33:58

which extends to the periurethral region on DCE, and this was treated with IRE.

34:03

So the patient came back for one-year follow-up.

34:06

So what we see here is, this is the ablation area with dark

34:12

T2 signal. But at the margin of the ablation zone, there's something intermediate

34:17

that showed up, and that shows restricted diffusion and also very early

34:21

enhancement. And if we were to apply PI-FAB and TARGET here, so let's start with

34:26

PI-FAB. So this is a lot of abnormal large area of enhancement that corresponds

34:32

to DWI and T2. So this would be score three because it's

34:38

early focal enhancement, which is definitely more than three millimeter.

34:41

So this would be high index of suspicion of recurrence for PI-FAB.

34:44

And if we're applying TARGET, because the score of BCE is itself three, the

34:50

cumulative score, which is five, which means that again, there's high index of

34:53

suspicion for recurrence. And this was sampled, and this turned out to be Gleason

34:57

grade four plus four recurrence at just at the margin of the ablation zone.

35:02

So again, take-home point for focal therapy as such is DCE

35:08

is the main sequence or dominant sequence.

35:11

But any post-treatment assessment, if the DCE is positive

35:17

abnormal, that really needs to raise alarm bells.

35:20

And at the same time, if you have positive restricted diffusion, that kind of

35:24

increases our diagnostic confidence to call it as a recurrence.

35:28

So just to summarize what we've seen so far is there

35:34

are different scoring systems for different treatment assessments.

35:38

For example, if the patient is on active surveillance, the current scoring system

35:42

that's available is PRECISE, and which also incorporates image quality, which is

35:46

PI-RADS well, and the current version is two.

35:48

And for whole gland therapy, whether it's prostatectomy or radiotherapy, we're

35:53

looking at PI-RADS. And the slight difference is if you were to choose to apply

35:57

this scoring as to how you approach prostatectomy versus radiotherapy.

36:01

And for focal therapy, currently, there are at least two scoring systems available.

36:07

One is PI-FAB, which is a three-point scale and scoring system, and TARGET is a

36:12

five-point scoring system. But irrespective of what we choose to use, the

36:18

dominant sequence is DCE. And as I said, based on a PIRADS

36:24

version two point one technique, the recommendation is having an axial T2 and at

36:28

least one orthogonal plane. But if you're looking at post-treatment changes, it's

36:32

good to have all the three planes And DCE becomes the dominant sequence for most of

36:38

these post-treatment assessment changes.

36:40

And when we're looking at ADC, especially for post-focal therapy, it's important to

36:45

read it along with the DWI, because sometimes fibrosis can also have low ADC.

36:50

Again, these are all still maturing systems, and you may or may not choose to

36:57

use these grading systems depending on your local practice.

37:00

But even if we don't use these scoring systems, the principles behind all

37:06

these systems are actually quite helpful for us to detect any recurrent cancers,

37:11

and that can be incorporated into how we approach these scans.

37:16

And these are my acknowledgments.

37:18

So most of my focal therapy work was from Singapore, and that's my crew from

37:22

Singapore. And

37:25

also my current residents, both from Sydney and Melbourne, have helped me with some

37:29

of the prostate work that went on into this PowerPoint as well.

37:33

And with that, thank you very much, and I've included my email.

37:37

If you want to get in touch, please feel free to do so.

37:43

And with that, I'm open for some questions and just going to have a quick look at

37:49

the chat to see if there are any questions.

37:54

Yeah. Thank you so much for that lecture.

37:55

We've got a question in the Q&A box if you can

37:59

click that.

38:02

Yeah. So I have a question here. So for both Pi-FAB target and PIR

38:08

post-radiotherapy scores, is there a time interval post-procedure that the MR will

38:13

be repeated? So for post-radiotherapy, I think there's enough evidence to

38:20

show that early on, there's still a lot of granulation tissue or reactive changes

38:26

that could result in spurious or challenges reading scans.

38:30

At least the current recommended time interval is at least three months for

38:34

radiotherapy. But oftentimes, the follow-up usually comes back within a year.

38:39

And in my previous institution in Singapore, our follow-ups are usually a minimum

38:44

time interval of one year, unless there's a high index of

38:50

suspicion for PSA and DRE. So usually, that's what we follow.

38:55

The next question is granulomatous prostatitis versus CSPC and pre

39:00

and post-treatment. This is always a challenge when we're looking

39:06

at granulomatous prostatitis versus CSPCA.

39:10

So the cases that we've come across for granulomatous prostatitis have had a

39:15

positive history for BCG oftentimes. So that's definitely helpful.

39:22

But otherwise, it can be quite challenging because granulomatous prostatitis can

39:26

also look like PIRADS five lesions, sometimes really hard to tell.

39:31

Okay. I think we'll close. Really appreciate you being here and giving us your time

39:36

for this awesome lecture.

39:38

Yeah. Thank you so much for having me. Thank you.

39:40

Of course, yes. And thanks for everyone else for signing on and participating in

39:43

today's noon conference. You can access a recording of today's conference and all

39:47

our previous ones by creating a free account.

39:50

We'll also email out a link to the replay later today.

39:53

Be sure to join us next week on Thursday, October 8th at 12:00 PM Eastern, where

39:58

Dr. Kevin Chang will deliver a lecture entitled "Diffuse Liver Disease." You can

40:02

register for that on vidality.com.

40:04

Follow us on social media for updates on future noon conferences.

40:07

Thanks again, and have a great day.

Report

Tags

Genitourinary (GU)

Body